4G/5G Polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome

Abstract

Purpose Polycystic ovary syndrome (PCOS) is one of the most encountered endocrine malfunctions. PCOS patients have enhanced activation of the blood coagulation system. Methods Eighty-six young women with PCOS and 70 healthy control women were included in our study. PCOS patients and controls were matched for age, body mass index, and allele frequency. Genetic analysis of TPAI and PAI-1 were performed in all subjects. Results and conclusions No statistically significant differences have been detected about the ratios of genotypes resulting from PAI-1 promotor 4G/5G gene polymorphism. PAI-1 765 4G/5G gene polymorphism and TPA gene's Alurepeat insertion/deletion (I/D) polymorphism ratios were not different from the controls. In this study it is shown by the analysis of TPA gene's Alu-repeat insertion/deletion (I/D) polymorphism the PCOS patients with genotype II had lowers total cholesterol and LDL-cholesterol levels.

Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome

“…We found 4G/5G heterozygote to be the most common genotype both in cases and controls. This was also consistent with the findings of a previous study, which evaluated the 4G/5G polymorphism in the promoter region of PAI-1 gene in Turkish population [36]. Similarly, Karadeniz et al [36] did not find an association between 4G/ 5G gene polymorphism and PCOS in Turkish population.…”

“…This was also consistent with the findings of a previous study, which evaluated the 4G/5G polymorphism in the promoter region of PAI-1 gene in Turkish population [36]. Similarly, Karadeniz et al [36] did not find an association between 4G/ 5G gene polymorphism and PCOS in Turkish population. These results are also in agreement with the previous observations of San Millán et al [34] and Walch et al [35], who also did not find any differences in the 4G/5G polymorphism between PCOS patients and controls.…”

“…A common diallelic polymorphism located at −675 bases from the transcription start site of PAI-1 is the best characterized genetic determinant. The 4G/5G polymorphism in the SERPINE1 gene has been linked with PCOS susceptibility [33], but no association was found in other studies [34][35][36].…”

Association of angiotensin converting enzyme (ACE) gene I/D polymorphism and polycystic ovary syndrome (PCOS)

“…Prominent features of the syndrome include hirsutism, menstrual dysfunction, infertility, elevated androgen levels and insulin resistance (Choi et al, 2009;Karadeniz et al, 2007;Özenli et al, 2008;Palep-Singh et al, 2007;Radakovic and Goldstajn, 2007;Tarkun et al, 2005;Tsanadis et al, 2002). Women with PCOS are also more likely to develop components of the metabolic syndrome such as diabetes, obesity, hypertension and dyslipidemia, which in turn are major risk factors for cardiovascular disease (Orio et al, 2003;Unsal et al, 2009).…”

Apolipoprotein E gene polymorphism and polycystic ovary syndrome patients in Western Anatolia, Turkey

“…Women with PCOS are more prone to have metabolic syndrome than healthy women [12]. Additionally, different markers of atherosclerosis, such as fibrinogen, high sensitive C-reactive protein, homocysteine, oxidative stress markers, PAI-1, TPA, carotid intimae-media thickness, and echocardiographic findings have also been found to be changed [13][14][15][16]. Dyslipidemia is very common and includes elevated triglyceride levels and low high-density lipoprotein (HDL) cholesterol concentrations in PCOS patients [17].…”